Povorcitinib Shows Positive Outcomes For Hidradenitis Suppurativa in phase 2 trial

A recent study published in the Journal of the American Academy of Dermatology found the potential benefits of povorcitinib, a selective oral Janus kinase 1 (JAK1) inhibitor for treating Hidradenitis Suppurativa (HS), a chronic skin condition marked by painful nodules and abscesses.
This placebo-controlled phase 2 study involved a total of 209 patients, povorcitinib exhibited significant promise in reducing both abscess and inflammatory nodule (AN) counts over a 16-week period. Patients were further randomized to receive varying doses of povorcitinib—15 mg, 45 mg, or 75 mg—or a placebo.
The findings revealed a notable decrease in AN counts compared to the placebo group. The least squares mean change from baseline in AN count for the povorcitinib groups were as follows: 15 mg (−5.2), 45 mg (−6.9), and 75 mg (−6.3), whereas the placebo group showed a change of −2.5. The results suggest that povorcitinib may effectively alleviate HS-associated inflammation.
Additionally, the study evaluated the percentage of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16. Povorcitinib-treated patients demonstrated a higher likelihood of achieving HiSCR compared to the placebo group: 15 mg (48.1%), 45 mg (44.2%), and 75 mg (45.3%) versus placebo (28.8%).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.